Physician profile
Brian J Stuart
NPI 1174564314
$4,818.34
in general payments reported to CMS, 2019-2025
47 companies · $1,049 in 2025
The $1,049 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $169 · 2020: $65.93 · 2021: $327 · 2022: $956 · 2023: $1,044 · 2024: $1,207 · 2025: $1,049.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,301.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,300.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,048.96 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $441.90 | 2019-2025 | |
| Abbvie INC. | $432.26 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Novartis Pharmaceuticals Corporation | $240.45 | 2019-2023 | |
| Lilly USA, LLC | $206.61 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Otsuka America Pharmaceutical, INC. | $206.43 | 2021-2025 | Rexulti |
| Exact Sciences Corporation | $203.93 | 2023-2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $161.91 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $147.84 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Astellas Pharma US INC | $141.90 | 2019-2025 | Veozah |
| Beta Bionics, INC. | $132.21 | 2023 | Ilet Bionic Pancreas |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.12 | 2019-2024 | Jardiance, Synjardy |
| Sumitomo Pharma America, INC. | $95.89 | 2023-2025 | Gemtesa |
| Xeris Pharmaceuticals, INC. | $94.37 | 2021-2024 | Gvoke Hypopen |
| Amgen INC. | $78.26 | 2019-2025 | Otezla, Repatha |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Stuart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.